adis r&d insight vendor update sla p&ht division meeting april 8, 2008
TRANSCRIPT
![Page 1: Adis R&D Insight Vendor Update SLA P&HT Division Meeting April 8, 2008](https://reader035.vdocuments.site/reader035/viewer/2022070305/5514f2ef55034693478b5f67/html5/thumbnails/1.jpg)
Adis R&D Insight™
Vendor UpdateSLA P&HT Division Meeting
April 8, 2008
![Page 2: Adis R&D Insight Vendor Update SLA P&HT Division Meeting April 8, 2008](https://reader035.vdocuments.site/reader035/viewer/2022070305/5514f2ef55034693478b5f67/html5/thumbnails/2.jpg)
• Total number of RDI drug profiles = 23,296Total number of RDI drug profiles = 23,296• Number of new profiles added per month = 80Number of new profiles added per month = 80• Number of significant updates per month = 992Number of significant updates per month = 992• Active drug profiles = 43.1% of the total database.Active drug profiles = 43.1% of the total database.• Inactive/discontinued drug profiles = 56.9% of database.Inactive/discontinued drug profiles = 56.9% of database.• Number of profiles with chemical structures = 8952Number of profiles with chemical structures = 8952• Number of companies covered = 3589Number of companies covered = 3589• Number of company profiles linked = 406 Number of company profiles linked = 406 • Number of companies tracked by Lehman Bros = 80-100Number of companies tracked by Lehman Bros = 80-100• Number of profiles with a Lehman table = 995Number of profiles with a Lehman table = 995• Therapeutic Area Coverage = ALL plus Diagnostic Therapeutic Area Coverage = ALL plus Diagnostic
agents, Cell therapies, Gene therapies and Vaccines.agents, Cell therapies, Gene therapies and Vaccines.• Number of Indications = 1283Number of Indications = 1283
*February 2008*February 2008
• Total number of RDI drug profiles = 23,296Total number of RDI drug profiles = 23,296• Number of new profiles added per month = 80Number of new profiles added per month = 80• Number of significant updates per month = 992Number of significant updates per month = 992• Active drug profiles = 43.1% of the total database.Active drug profiles = 43.1% of the total database.• Inactive/discontinued drug profiles = 56.9% of database.Inactive/discontinued drug profiles = 56.9% of database.• Number of profiles with chemical structures = 8952Number of profiles with chemical structures = 8952• Number of companies covered = 3589Number of companies covered = 3589• Number of company profiles linked = 406 Number of company profiles linked = 406 • Number of companies tracked by Lehman Bros = 80-100Number of companies tracked by Lehman Bros = 80-100• Number of profiles with a Lehman table = 995Number of profiles with a Lehman table = 995• Therapeutic Area Coverage = ALL plus Diagnostic Therapeutic Area Coverage = ALL plus Diagnostic
agents, Cell therapies, Gene therapies and Vaccines.agents, Cell therapies, Gene therapies and Vaccines.• Number of Indications = 1283Number of Indications = 1283
*February 2008*February 2008
Adis R&D Insight - StatisticsAdis R&D Insight - Statistics
![Page 3: Adis R&D Insight Vendor Update SLA P&HT Division Meeting April 8, 2008](https://reader035.vdocuments.site/reader035/viewer/2022070305/5514f2ef55034693478b5f67/html5/thumbnails/3.jpg)
Adis R&D Insight: Sources
• Detailed drug profiles derived from the following sources– Company contacts– Press releases– International conferences– Company websites– More than 1,300 biomedical / medical journals
• Detailed drug profiles derived from the following sources– Company contacts– Press releases– International conferences– Company websites– More than 1,300 biomedical / medical journals
![Page 4: Adis R&D Insight Vendor Update SLA P&HT Division Meeting April 8, 2008](https://reader035.vdocuments.site/reader035/viewer/2022070305/5514f2ef55034693478b5f67/html5/thumbnails/4.jpg)
Adis R&D Insight NEW! For 2007/2008
• Upgraded search functionality• Improved ease of use• Links to original sources• Major improvements to customizing
preferences and push alerting
![Page 5: Adis R&D Insight Vendor Update SLA P&HT Division Meeting April 8, 2008](https://reader035.vdocuments.site/reader035/viewer/2022070305/5514f2ef55034693478b5f67/html5/thumbnails/5.jpg)
BROWSE function
Separate lists for Biological and Chemical classes
List View/Tree View option
Allows searching on synonyms
Upgraded Search FunctionalityBiological and Chemical Class
![Page 6: Adis R&D Insight Vendor Update SLA P&HT Division Meeting April 8, 2008](https://reader035.vdocuments.site/reader035/viewer/2022070305/5514f2ef55034693478b5f67/html5/thumbnails/6.jpg)
Route and Formulation
New tab allows search by
• Route of administration
• Formulation
Upgraded Search Functionality
![Page 7: Adis R&D Insight Vendor Update SLA P&HT Division Meeting April 8, 2008](https://reader035.vdocuments.site/reader035/viewer/2022070305/5514f2ef55034693478b5f67/html5/thumbnails/7.jpg)
Upgraded Search Functionality
Organization Renamed parameter for better classification of drug developers Search by Organization Type or Ownership Type
![Page 8: Adis R&D Insight Vendor Update SLA P&HT Division Meeting April 8, 2008](https://reader035.vdocuments.site/reader035/viewer/2022070305/5514f2ef55034693478b5f67/html5/thumbnails/8.jpg)
Phase
‘Highest Phase’ and ‘Phase is’ New ‘Phase filter’ option Updated and expanded Phase list
Upgraded Search Functionality
![Page 9: Adis R&D Insight Vendor Update SLA P&HT Division Meeting April 8, 2008](https://reader035.vdocuments.site/reader035/viewer/2022070305/5514f2ef55034693478b5f67/html5/thumbnails/9.jpg)
Country Hierarchy
• Country searching is expanded to provide the ability to confidently and simply search by broad geographical / political region.
• Addition of ‘Tree View’
Upgraded Search Functionality
![Page 10: Adis R&D Insight Vendor Update SLA P&HT Division Meeting April 8, 2008](https://reader035.vdocuments.site/reader035/viewer/2022070305/5514f2ef55034693478b5f67/html5/thumbnails/10.jpg)
Fast Track
• Allows to search compounds that were assigned Fast Track status by the FDA in the US
Upgraded Search Functionality
![Page 11: Adis R&D Insight Vendor Update SLA P&HT Division Meeting April 8, 2008](https://reader035.vdocuments.site/reader035/viewer/2022070305/5514f2ef55034693478b5f67/html5/thumbnails/11.jpg)
‘Orphan Drug’
Orphan Drug designation for a particular indication
Orphan designation country
‘Any Indication or Country’: search ALL profiles were Orphan Drug exists
Upgraded Search Functionality
![Page 12: Adis R&D Insight Vendor Update SLA P&HT Division Meeting April 8, 2008](https://reader035.vdocuments.site/reader035/viewer/2022070305/5514f2ef55034693478b5f67/html5/thumbnails/12.jpg)
Full Text
‘Full Text’ has replaced the ‘Text Contains’ free text searching option.
Can be partnered with a Category, which will search a specific part of the profile.
Search term will be highlighted in yellow when you open the profile
Upgraded Search Functionality
![Page 13: Adis R&D Insight Vendor Update SLA P&HT Division Meeting April 8, 2008](https://reader035.vdocuments.site/reader035/viewer/2022070305/5514f2ef55034693478b5f67/html5/thumbnails/13.jpg)
Addition of Disease Qualifiersa qualifier may be added to an indicationa qualifier comment can be added to provide additional information
Improved Ease of Use
![Page 14: Adis R&D Insight Vendor Update SLA P&HT Division Meeting April 8, 2008](https://reader035.vdocuments.site/reader035/viewer/2022070305/5514f2ef55034693478b5f67/html5/thumbnails/14.jpg)
More Tabular Content
Route listed in Phase of Development Table
Orphan Designation
Brand Name Table
Improved Ease of Use
![Page 15: Adis R&D Insight Vendor Update SLA P&HT Division Meeting April 8, 2008](https://reader035.vdocuments.site/reader035/viewer/2022070305/5514f2ef55034693478b5f67/html5/thumbnails/15.jpg)
Links to Original Sources
Journal FullText option in recordsOpen access linking capability to link
to your journal holdings
![Page 16: Adis R&D Insight Vendor Update SLA P&HT Division Meeting April 8, 2008](https://reader035.vdocuments.site/reader035/viewer/2022070305/5514f2ef55034693478b5f67/html5/thumbnails/16.jpg)
Results Page
Choose Columns for viewing on Results Page
Customization
![Page 17: Adis R&D Insight Vendor Update SLA P&HT Division Meeting April 8, 2008](https://reader035.vdocuments.site/reader035/viewer/2022070305/5514f2ef55034693478b5f67/html5/thumbnails/17.jpg)
Development table
Filtering by search
Sorting by heading
Customization
![Page 18: Adis R&D Insight Vendor Update SLA P&HT Division Meeting April 8, 2008](https://reader035.vdocuments.site/reader035/viewer/2022070305/5514f2ef55034693478b5f67/html5/thumbnails/18.jpg)
New ALERTS features:
Multiple email addresses can be set up for a single email alert
Searches from both R&D Insight and Clinical Trials Insight can be included in a single alert
Users will be able to export, print, chart results from their Alerts
Run search from last alert
Alerts
![Page 19: Adis R&D Insight Vendor Update SLA P&HT Division Meeting April 8, 2008](https://reader035.vdocuments.site/reader035/viewer/2022070305/5514f2ef55034693478b5f67/html5/thumbnails/19.jpg)
Customer Engagement Activities- 2007Customer Engagement Activities- 2007
• Online Surveys conducted• Key Takeaways
– Areas of expanding importance are drug targets and new formulations
– Greater need for financial data, patent, and licensing/deals opportunities
– Improved ability in accessing specific data points
– Timeliness and comprehensiveness is critical
• Online Surveys conducted• Key Takeaways
– Areas of expanding importance are drug targets and new formulations
– Greater need for financial data, patent, and licensing/deals opportunities
– Improved ability in accessing specific data points
– Timeliness and comprehensiveness is critical
![Page 20: Adis R&D Insight Vendor Update SLA P&HT Division Meeting April 8, 2008](https://reader035.vdocuments.site/reader035/viewer/2022070305/5514f2ef55034693478b5f67/html5/thumbnails/20.jpg)
Next Steps for Adis R&D InsightNext Steps for Adis R&D Insight
• Customer roundtables to determine and continue to drive specific major enhancements– US and Europe during the weeks
of March 31st and April 4th – Representation from all user and
customer types• Improve comprehensiveness of
coverage through the content acquisition initiative (technology and process review)
• Customer roundtables to determine and continue to drive specific major enhancements– US and Europe during the weeks
of March 31st and April 4th – Representation from all user and
customer types• Improve comprehensiveness of
coverage through the content acquisition initiative (technology and process review)